^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:taselisib (GDC-0032) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Taselisib (GDC-0032), a Potent ß-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

    Excerpt:
    In Cal-33 cells (PIK3CAH1047R), the combination of GDC-0032 and radiation resulted in both more apoptotic (Annexin V–positive, PI-negative) and nonapoptotic (Annexin V–positive, PI-negative) cell death than either treatment alone (Fig. 3A).
    DOI:
    10.1158/1078-0432.CCR-15-2245